Table 2 Treatment details from the Saudi MS registry by disease course
Medications | RRMS n (%) | SPMS n (%) | PPMS n (%) | PRMS n (%) | Total n (%) |
|---|---|---|---|---|---|
Relapse | 2003 (92) | 137 (6.3) | 35 (1.6) | 12 (0.6) | 2177 (47.2) |
Corticosteroids | 1998 (99.7) | 127 (100) | 35 (100) | 12 (100) | 2172 (99.7) |
DMTs | 2296 (92.6) | 131 (5.3) | 35 (1.4) | 18 (0.7) | 2480 (52.8 * ) |
Teriflunomoide | 101(4.4) | 6 (4.58) | 0 (0.0) | 1 (5.56) | 108 (4.35) |
Avonex (interferon beta-1a) | 466 (20.3) | 26 (19.85) | 7 (17.5) | 2 (11.11) | 501 (20.16) |
Betaserone (interferon beta-1b) | 562 (24.48) | 29 (22.14) | 13 (32.5) | 6 (33.33) | 610 (24.55) |
Glatiramer acetate | 10 (0.44) | 1 (0.76) | 0 (0.0) | 1 (5.56) | 12 (0.48) |
Fingolimod | 325 (14.16) | 18 (13.74) | 5 (12.5) | 2 (11.11) | 350 (14.08) |
Alemtuzumab | 6 (0.26) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (0.24) |
Mitoxantrone | 6 (0.26) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (0.24) |
Rebif (interferon beta-1a) | 507 (22.08) | 36 (27.48) | 7 (17.5) | 4 (22.22) | 554 (22.29) |
Rituximab | 21 (0.91) | 1 (0.76) | 1 (2.50) | 0 (0.0) | 23 (0.93) |
Dimethyl fumarate | 36 (1.57) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 36 (1.45) |
Natalizumab | 256 (11.15) | 14 (10.69) | 2 (5.0) | 2 (11.11) | 274 (11.03) |